Renal Cell Carcinoma

P2, N=66, Active, not recruiting, Ontario Clinical Oncology Group (OCOG) | Trial completion date: Apr 2026 --> Jul 2026

However, a positive correlation between RSUME and HIF-1α expression was observed (p < 0.05). These results suggested that upregulated expression of RSUME may be involved in the formation and progression of renal cell carcinoma via interaction with VHL/HIF-1α signalling pathway, and thus RSUME may be a novel potential therapeutic target for renal cell carcinoma.

Remaining challenges include uncertainty regarding the identification of predictive biomarkers, optimization of patient selection, and integration of combination or sequencing strategies. Beyond its immediate clinical impact, belzutifan establishes a foundation for next-generation hypoxia-targeted therapies.

Tissue based quantification of CD47 and CD20 might be used to predict response to ICI in mRCC. Both markers influence the anti-tumor response and seem to be markers of a highly immune-infiltrated, and simultaneously functional immunosuppressed TME which seem to profit the most from ICI. Therefore, CD47 and CD20 could be suitable to discriminate between patients which profit from those who would not profit from ICI and avoid unnecessary costs due to side effects.

Importantly, clinical benefit from ICIs was negatively correlated with the TMREhigh CD8 T cell gene expression signature. These findings highlight a T cell population characterized by elevated MMP that correlates with exhaustion-like transcriptional states and poor response to immunotherapy.

Importantly, the tumor-promoting functions of JOSD2 were found to be largely dependent on CREB1 activity. Together, these results support a role for the JOSD2-CREB1 reciprocal axis in glycolysis-associated RCC progression and suggest its potential prognostic and therapeutic relevance.

These findings suggest that ALDH1L2 contributes to reduced sunitinib sensitivity in RCC organoids by attenuating ferroptosis-related responses. HA-1 may improve the response of RCC organoids to sunitinib by targeting ALDH1L2, supporting further evaluation of this combination strategy.

In conclusion, the findings of this study elucidate the involvement of NCBP1 in the malignant progression of WT. NCBP1 enhances the stability of KPNA2 mRNA, thereby upregulating KPNA2 expression and subsequently promoting the malignant progression of WT cells.

P=N/A, N=623, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed

P1/2, N=55, Recruiting, University of Chicago | Not yet recruiting --> Recruiting

P=N/A, N=33, Recruiting, Yale University | N=10 --> 33 | Trial completion date: Dec 2027 --> Dec 2030 | Trial primary completion date: Dec 2027 --> Dec 2030

We also discussed some emerging methodologies, including metabolic imaging and spatial profiling approaches, to address intratumoral metabolic heterogeneity. Overall, this review emphasizes how leveraging RCC-specific metabolic vulnerabilities can inform precision medicine approaches and improve therapeutic outcomes for patients with RCC.